Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Сравнительная оценка зофеноприла: значимы ли для клиники особенности ингибиторов ангиотензинпревращающего фермента? - Журнал Системные Гипертензии Том 11, №3
Сравнительная оценка зофеноприла: значимы ли для клиники особенности ингибиторов ангиотензинпревращающего фермента?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье дан обзор основных сравнительных исследований антигипертензивной эффективности и кардиопротективных свойств зофеноприла. Приведены данные о преимуществах препаратов с высокой тканевой доступностью в профилактике гипертрофии левого желудочка и повышения его жесткости, наличии у ряда препаратов антиатеросклеротических и антиишемических эффектов. Результаты приведенных исследований, раскрывая особенности действия препаратов данного класса, расширяют возможности практикующих врачей в лечении больных артериальной гипертензией с сопутствующей стенокардией, перенесших острый инфаркт миокарда.
Ключевые слова: зофеноприл, артериальная гипертензия, инфаркт миокарда.
Key words: zofenopril, arterial hypertension, heart attack.
Ключевые слова: зофеноприл, артериальная гипертензия, инфаркт миокарда.
________________________________________________
Key words: zofenopril, arterial hypertension, heart attack.
Полный текст
Список литературы
1. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5 (9): 1965–77.
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 13–8.
3. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 25–30.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 2 (Suppl.): 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 2 (Suppl.): 19–24.
6. Malacco E, Piazza S, Omboni S on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Tuagi SC, Cleutjens JP. J Mol Cell Cardiol 1994; 26: 279–92.
9. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998; 37–44.
10. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
11. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
12. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi С, Ambrosioni E, Magnani B. Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction. Am J Cardiol 1996; 78: 317–22.
15. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
16. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
17. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.
18. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
19. Borghi C, Ambrosioni E, Novo S et al. Оn behalf of the SMILE-4 Working Party. Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acidin Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4). Clin Cardiol 2012; DOI:10.1002/clc.22017.
20. Borghi C, Ambrosioni E, Omboni S et al. Cost-effectiveness of zofenopril in patientswith left ventricular systolic dysfunctionafter acute myocardial infarction: a posthoc analysis of SMILE-4. Clinico Economics and Outcomes Research 2013; 5: 317–25.
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 13–8.
3. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 25–30.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 2 (Suppl.): 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 2 (Suppl.): 19–24.
6. Malacco E, Piazza S, Omboni S on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Tuagi SC, Cleutjens JP. J Mol Cell Cardiol 1994; 26: 279–92.
9. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998; 37–44.
10. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
11. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
12. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi С, Ambrosioni E, Magnani B. Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction. Am J Cardiol 1996; 78: 317–22.
15. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
16. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
17. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.
18. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
19. Borghi C, Ambrosioni E, Novo S et al. Оn behalf of the SMILE-4 Working Party. Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acidin Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4). Clin Cardiol 2012; DOI:10.1002/clc.22017.
20. Borghi C, Ambrosioni E, Omboni S et al. Cost-effectiveness of zofenopril in patientswith left ventricular systolic dysfunctionafter acute myocardial infarction: a posthoc analysis of SMILE-4. Clinico Economics and Outcomes Research 2013; 5: 317–25.
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 13–8.
3. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 25–30.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 2 (Suppl.): 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 2 (Suppl.): 19–24.
6. Malacco E, Piazza S, Omboni S on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Tuagi SC, Cleutjens JP. J Mol Cell Cardiol 1994; 26: 279–92.
9. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998; 37–44.
10. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
11. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
12. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi С, Ambrosioni E, Magnani B. Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction. Am J Cardiol 1996; 78: 317–22.
15. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
16. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
17. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.
18. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
19. Borghi C, Ambrosioni E, Novo S et al. Оn behalf of the SMILE-4 Working Party. Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acidin Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4). Clin Cardiol 2012; DOI:10.1002/clc.22017.
20. Borghi C, Ambrosioni E, Omboni S et al. Cost-effectiveness of zofenopril in patientswith left ventricular systolic dysfunctionafter acute myocardial infarction: a posthoc analysis of SMILE-4. Clinico Economics and Outcomes Research 2013; 5: 317–25.
________________________________________________
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 13–8.
3. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 25–30.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 2 (Suppl.): 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 2 (Suppl.): 19–24.
6. Malacco E, Piazza S, Omboni S on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Tuagi SC, Cleutjens JP. J Mol Cell Cardiol 1994; 26: 279–92.
9. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998; 37–44.
10. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
11. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
12. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi С, Ambrosioni E, Magnani B. Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction. Am J Cardiol 1996; 78: 317–22.
15. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
16. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
17. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.
18. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
19. Borghi C, Ambrosioni E, Novo S et al. Оn behalf of the SMILE-4 Working Party. Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acidin Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4). Clin Cardiol 2012; DOI:10.1002/clc.22017.
20. Borghi C, Ambrosioni E, Omboni S et al. Cost-effectiveness of zofenopril in patientswith left ventricular systolic dysfunctionafter acute myocardial infarction: a posthoc analysis of SMILE-4. Clinico Economics and Outcomes Research 2013; 5: 317–25.
Авторы
А.А.Кириченко
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.